Dermatologic Reactions in Patients Undergoing EGFR-Pathway Targeted Therapies
Background
Epidermal growth factor receptor (EGFR)-directed therapies are essential in cancer treatment but are often accompanied by dermatologic adverse events. Papulopustular eruptions, distinct from acne vulgaris, are among the most common toxicities, affecting patient quality of life and treatment continuity.
Data Highlights
No numerical data or trial data presented in the source material.
Key Findings
Papulopustular eruptions are a characteristic toxicity of classical EGFR inhibitors.
These eruptions are distinct from acne vulgaris, lacking comedones and arising closely with therapy initiation.
MEK inhibitors and newer EGFR-targeting therapies like amivantamab also present similar dermatologic reactions.
Mechanistic studies suggest involvement of KLF4/IL-36γ signaling and Cutibacterium acnes in inflammation.
Evidence supporting management strategies varies, with conventional care being well-supported compared to newer, complex phenotypes.
Clinical Implications
Healthcare providers should be aware of the distinct nature of EGFR inhibitor-associated dermatologic reactions and the importance of early intervention.
Conclusion
Understanding the complexities of dermatologic reactions to EGFR-targeted therapies is essential for effective patient management.
